Press release
Inflammatory Bowel Disease Ibd Market 2018-2026 major industry players- Pfizer Inc., Shire Plc., Janssen Biotech, Inc., AbbVie Inc., Allergan plc., Novartis AG
The Global Inflammatory Bowel Disease Market Size to gain traction owning to the factors such as increasing population suffering with IBD that is majorly influenced by the changing lifestyle preferences across the globe.Inflammatory Bowel Disease is the type of gastrointestinal inflammatory disease. This disease causes long term chronic and severe inflammation in the intestinal tract. Similarly, it can be termed as an inflammatory condition to the colon and small intestine. Inflammatory bowel disease (IBD) on the basis of indication is segmented into Crohn’s disease, and ulcerative colitis. Crohn’s disease not only affects the small intestine but also has the ability to affect the mouth, stomach, the anus, and oesophagus. Whereas, ulcerative colitis affects the rectum and the colon. The number of patients suffering from IBD is on rise due to changing lifestyle globally. According to CDC, there are more than 70,000 new cases of IBD every year in North America.
Request to Sample of This Report @ https://www.polarismarketresearch.com/industry-analysis/global-inflammatory-bowel-disease-ibd-market/request-for-free-sample
In the recent years, there are various research studies that have been focusing on the causes of inflammatory bowel disease. The major causes of IBD includes the genetic mutations that are caused in NOD2/CARD15 gene, and virus or bacteria. In general, inflammatory bowel disease (IBD) is majorly caused by immune malfunctioning, in which the immune system attacks the healthy cells in digestive tract. The factors like age, ethnicity, cigarette smoking, intake of non-steroidal anti-inflammatory medications, and family history support the growth of IBD. The common symptoms observed in an individual suffering from IBD are persistent diarrhoea, cramps in abdomen, fever, and occasional rectal bleeding.
The global inflammatory bowel disease is primarily driven by rising prevalence of inflammatory bowel disease globally. Moreover, the rising preference & intake of fast food, and increasing sedentary lifestyle is responsible to promote the growth of this market in the near future. In addition, the stressful life of the people also influences the global market. Similarly, rising government initiatives for analysing the causes and effective new drug development is expected to create further surge in inflammatory bowel disease (IBD) market.
Inflammatory bowel disease is treated with immunomodulators, corticosteroids, aminosalicyclates, and TNF inhibitors. TNF inhibitors are the most preferred drug class for treating IBD. It holds the major market share in the IBD market owning to their effectiveness and awareness for treating IBD. On the other hand, positive approach for using immunotherapies would also spur the market.
Request for an in-depth table of contents for this report @ https://www.polarismarketresearch.com/industry-analysis/global-inflammatory-bowel-disease-ibd-market/speak-to-analyst
Increased prevalence of Ulcerative Colitis and Crohn’s Disease to lead the market growth in North America.
Geographically, the global market to be segmented as North America, Europe, Asia Pacific, Latin America & Middle East and Africa. North America region is expected to dominate this market over the forecast period. North America holds major share owning to the rising number of patients suffering from ulcerative colitis and Crohn’s disease, and changed diet preferences in this region. Moreover, well established healthcare infrastructure by the governments in North America to boom the inflammatory bowel disease market in the near future.
However, Asia Pacific to grow at a faster pace in the forecast period. Higher population in this region, and increased preference for sedentary lifestyle in the developing countries are the major factors that anticipated to govern the growth in Asia Pacific market during upcoming years.
Key players in the global inflammatory bowel disease market are:
• Pfizer Inc.
• Shire Plc.
• Janssen Biotech, Inc.
• AbbVie Inc.
• Allergan plc.
• Novartis AG
• UCB Inc.
• Biogen Inc.
• Valent Pharmaceuticals International, Inc.
• Takeda Pharmaceuticals Company Limited.
Make an Inquiry for purchasing this report @ https://www.polarismarketresearch.com/industry-analysis/global-inflammatory-bowel-disease-ibd-market/inquire-before-buying
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.
Contact us
Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: neel@polarismarketresearch.com
Web: www.polarismarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Inflammatory Bowel Disease Ibd Market 2018-2026 major industry players- Pfizer Inc., Shire Plc., Janssen Biotech, Inc., AbbVie Inc., Allergan plc., Novartis AG here
News-ID: 1300449 • Views: …
More Releases from Polaris Market Research & Consulting

Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of …
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. It…

Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 …
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected to…

Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin …
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billion…

Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 …
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reach…
More Releases for IBD
Ace Therapeutics Unveils Imaging Services for Precise Characterization of IBD An …
Ace Therapeutics launched its translational imaging services specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models.
New York, USA - May 28, 2025 - Ace Therapeutics, a leader in preclinical research solutions, launched its translational imaging solutions specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. This breakthrough offering empowers researchers with high-resolution, quantitative data to enhance drug development and mechanistic studies.
Image: https://www.getnews.info/uploads/3c0755ac659fa5075e809ffd1b893496.jpg
Imaging techniques play a crucial…
Inflammatory Bowel Disease (IBD) Market Size, Growth Insights, and Future Trends
Inflammatory Bowel Disease (IBD) continues to pose significant challenges for individuals and healthcare systems worldwide. With its increasing prevalence, the demand for effective treatments is driving market growth. The IBD treatment market is projected to grow from USD 19.91 billion in 2023 to USD 33.19 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period.
Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5149
Key Market Highlights
• Crohn's Disease Dominates: Crohn's disease…
Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,…
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios.
Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx…
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per…
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and…